^
    Back
    Association details:
    Biomarker:NF1 mutation
    Cancer:Solid Tumor
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

    Excerpt:
    ...- Patients be >= 18 years old at the time of enrollment and must have a documented germline neurofibromatosis 1 (NF1) mutation in a Clinical Laboratory Improvement Act (CLIA) certified laboratory or a diagnosis of NF1 based on clinical National Institutes of Health (NIH) consensus criteria; in addition to substantial cutaneous neurofibroma burden, at least one of the criteria below have to be present...
    Trial ID:
    NCT02839720
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

    Excerpt:
    ...NF1 mutation analysis will be performed on germline DNA as described by Messiaen & Wimmer 52....
    Trial ID:
    SPRINT
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

    Excerpt:
    ...must have either a clinical diagnosis of NF1 or a germline NF1 mutation, or in patients without the NF1 syndrome, demonstrate an NF1 mutation in the GIST verified in a CLIA certified laboratory....
    Trial ID:
    NCT03109301
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Selumetinib Pilot Study for Cutaneous Neurofibromas

    Excerpt:
    ...- Patients must be ≥ 18 years old at the time of enrollment and have a documented germline NF1 mutation in a CLIA certified laboratory or a diagnosis of NF1 based on clinical NIH consensus criteria....
    Trial ID:
    NCT03105258
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

    Excerpt:
    ...- - Patients must have a documented germline NF1 mutation in a CLIA certified laboratory or a diagnosis of NF1 based on clinical NIH consensus criteria51 of at least one other diagnostic criterion in addition to the presence of a PN. ...
    Trial ID:
    NCT02644512
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial. Add to Collection

    Published date:
    05/19/2021
    Excerpt:
    Selumetinib did not result in tumor regression in this cohort of children and young adults with treatment-refractory tumors with activating MAPK pathway alterations. 
    DOI:
    10.1200/JCO.2021.39.15_suppl.10008
    Trial ID:
    MATCH